JP2016538240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538240A5 JP2016538240A5 JP2016516911A JP2016516911A JP2016538240A5 JP 2016538240 A5 JP2016538240 A5 JP 2016538240A5 JP 2016516911 A JP2016516911 A JP 2016516911A JP 2016516911 A JP2016516911 A JP 2016516911A JP 2016538240 A5 JP2016538240 A5 JP 2016538240A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- acid sequence
- amino acid
- target
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882377P | 2013-09-25 | 2013-09-25 | |
| US61/882,377 | 2013-09-25 | ||
| US201461971332P | 2014-03-27 | 2014-03-27 | |
| US61/971,332 | 2014-03-27 | ||
| PCT/US2014/057523 WO2015048329A2 (en) | 2013-09-25 | 2014-09-25 | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019173550A Division JP2020015749A (ja) | 2013-09-25 | 2019-09-24 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538240A JP2016538240A (ja) | 2016-12-08 |
| JP2016538240A5 true JP2016538240A5 (enExample) | 2017-11-09 |
| JP6915987B2 JP6915987B2 (ja) | 2021-08-11 |
Family
ID=51691175
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516911A Active JP6915987B2 (ja) | 2013-09-25 | 2014-09-25 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
| JP2019173550A Pending JP2020015749A (ja) | 2013-09-25 | 2019-09-24 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
| JP2021080015A Withdrawn JP2021138707A (ja) | 2013-09-25 | 2021-05-10 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
| JP2023122426A Pending JP2023159099A (ja) | 2013-09-25 | 2023-07-27 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
| JP2024186751A Active JP7806174B2 (ja) | 2013-09-25 | 2024-10-23 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019173550A Pending JP2020015749A (ja) | 2013-09-25 | 2019-09-24 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
| JP2021080015A Withdrawn JP2021138707A (ja) | 2013-09-25 | 2021-05-10 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
| JP2023122426A Pending JP2023159099A (ja) | 2013-09-25 | 2023-07-27 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
| JP2024186751A Active JP7806174B2 (ja) | 2013-09-25 | 2024-10-23 | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20150087810A1 (enExample) |
| EP (1) | EP3049111A2 (enExample) |
| JP (5) | JP6915987B2 (enExample) |
| KR (3) | KR102488220B1 (enExample) |
| CN (3) | CN118165076A (enExample) |
| AU (4) | AU2014324884B2 (enExample) |
| CA (2) | CA2925106C (enExample) |
| IL (3) | IL322893A (enExample) |
| MX (2) | MX379106B (enExample) |
| NZ (2) | NZ718283A (enExample) |
| RU (1) | RU2715232C2 (enExample) |
| WO (1) | WO2015048329A2 (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| MX2015016329A (es) | 2013-05-28 | 2016-07-20 | Dcb Usa Llc | Bloqueador de anticuerpo para la inactivacion de farmaco de proteina. |
| KR102488220B1 (ko) | 2013-09-25 | 2023-01-12 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| KR102466591B1 (ko) | 2014-01-31 | 2022-11-14 | 싸이톰스 테라퓨틱스, 인크. | 마트립타제 및 ｕ-플라스미노겐 활성화인자 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| KR102754019B1 (ko) | 2014-10-29 | 2025-01-14 | 바이시클러드 리미티드 | Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| EP3903818A1 (en) | 2015-11-19 | 2021-11-03 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| MX2019005756A (es) | 2016-11-28 | 2019-08-14 | Chugai Pharmaceutical Co Ltd | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
| TW202235438A (zh) | 2016-11-28 | 2022-09-16 | 日商中外製藥股份有限公司 | 能夠調節配體結合活性的配體結合分子 |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| KR20190089034A (ko) | 2016-12-09 | 2019-07-29 | 시애틀 지네틱스, 인크. | 코일드 코일에 의해 차폐된 이가 항체 |
| WO2018191438A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| US11939385B2 (en) | 2017-05-16 | 2024-03-26 | ALX Oncology Inc. | Activatable antibodies and methods of use thereof |
| CN107501394B (zh) * | 2017-06-19 | 2021-02-26 | 天津医科大学 | 高特异性mmp-14底物肽及其制备方法和应用 |
| CN111032678A (zh) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | 具有可检测部分的双环肽配体和其用途 |
| ES2926195T3 (es) | 2017-08-04 | 2022-10-24 | Bicycletx Ltd | Ligandos peptídicos bicíclicos específicos de CD137 |
| CN111278461A (zh) * | 2017-08-16 | 2020-06-12 | 百时美施贵宝公司 | 可前药化抗体、其前药以及使用和制备方法 |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| EP3719035A4 (en) | 2017-11-28 | 2021-09-01 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE WITH ANTIGEN-BINDING AREA AND CARRYING SECTION |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| TWI831759B (zh) | 2017-12-01 | 2024-02-11 | 美商思進公司 | Cd47抗體及其用於治療癌症之用途 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| AU2019224659A1 (en) | 2018-02-23 | 2020-10-15 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| IL277863B2 (en) | 2018-04-11 | 2026-02-01 | Inhibrx Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| WO2019222275A2 (en) * | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2019222294A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| JPWO2019230868A1 (ja) | 2018-05-30 | 2021-06-24 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| JP7428661B2 (ja) * | 2018-05-30 | 2024-02-06 | 中外製薬株式会社 | Ｉｌ－１ｒ１結合ドメインおよび運搬部分を含むポリペプチド |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| CA3105891A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| WO2020037236A1 (en) | 2018-08-17 | 2020-02-20 | Massachusetts Institute Of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| CN113518647A (zh) | 2018-10-11 | 2021-10-19 | 印希比股份有限公司 | 5t4单域抗体及其治疗性组合物 |
| CA3115082A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| SG11202105476XA (en) | 2018-12-06 | 2021-06-29 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| US12551567B2 (en) | 2018-12-21 | 2026-02-17 | Bicyclerd Limited | Bicyclic peptide ligands specific for PD-L1 |
| CN113474045A (zh) | 2018-12-21 | 2021-10-01 | 拜斯科技术开发有限公司 | Pd-l1特异性的双环肽配体 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| AU2020240310A1 (en) | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
| HUE065484T2 (hu) | 2019-04-26 | 2024-05-28 | Immunogen Inc | Camptothecin-származékok |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| AU2020278465B2 (en) | 2019-05-20 | 2026-04-23 | Dana-Farber Cancer Institute, Inc. | Boronic ester prodrugs and uses thereof |
| KR20220044904A (ko) | 2019-05-31 | 2022-04-12 | 알렉소 온콜로지 인크. | 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법 |
| WO2020247574A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Methods of purifying masked antibodies |
| JPWO2020246563A1 (enExample) | 2019-06-05 | 2020-12-10 | ||
| WO2020247572A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Masked antibody formulations |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| CN114845710A (zh) | 2019-11-27 | 2022-08-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| WO2021141662A1 (en) | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
| EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc. | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
| IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Monodomain antibodies of cd28 and their multivalent and multispecific constructs |
| CA3174665A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| JP2023520922A (ja) | 2020-04-10 | 2023-05-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能サイトカイン構築物および関連組成物ならびに方法 |
| CA3189761A1 (en) | 2020-08-03 | 2022-02-10 | Gemma Mudd | Peptide-based linkers |
| CN117015403A (zh) * | 2021-02-25 | 2023-11-07 | 上海联进生物科技有限公司 | 含效应分子的靶向缀合物及其用途 |
| CA3211924A1 (en) | 2021-03-16 | 2022-09-22 | Sayantan Mitra | Masked activatable cytokine constructs and related compositions and methods |
| BR112023022774A2 (pt) | 2021-05-13 | 2024-01-02 | Alx Oncology Inc | Terapias de combinação para tratamento de câncer |
| WO2023288236A1 (en) | 2021-07-14 | 2023-01-19 | Seagen Inc. | Antibody masking domains |
| US20230065782A1 (en) * | 2021-07-14 | 2023-03-02 | Oncoimmunin, Inc. | Targeted and localized in vivo delivery of oligonucleotides |
| US20240384323A1 (en) | 2021-08-30 | 2024-11-21 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| WO2023049825A1 (en) | 2021-09-24 | 2023-03-30 | Seagen Inc. | Improved antibody masking domains |
| AU2022361492A1 (en) | 2021-10-08 | 2024-05-02 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| AU2022360371A1 (en) | 2021-10-08 | 2024-05-02 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and combination methods |
| TW202323282A (zh) | 2021-10-15 | 2023-06-16 | 美商賽特艾克斯生物製藥公司 | 可活化之多肽複合物 |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| KR20240115809A (ko) | 2021-10-15 | 2024-07-26 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 폴리펩타이드 복합체 |
| US20250333539A1 (en) | 2022-03-23 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| US20260015425A1 (en) | 2022-08-01 | 2026-01-15 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| EP4565260A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130080A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| EP4565250A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| US20260049148A1 (en) | 2022-08-01 | 2026-02-19 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| JP2026513839A (ja) | 2023-04-12 | 2026-05-01 | サイトムエックス セラピューティクス，インク． | マスキングポリペプチド、活性化可能サイトカイン構成体、ならびに関連する組成物及び方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| AU2024363074A1 (en) * | 2023-10-19 | 2026-05-14 | Unovel (Shanghai) Biopharma Co., Ltd. | Polypeptide, bioactive conjugate, and preparation method therefor and use thereof |
| AR134512A1 (es) | 2023-12-01 | 2026-01-21 | Ablynx Nv | Polipéptidos activados con precisión |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| ZA974084B (en) * | 1996-05-10 | 1998-02-23 | Danisco | Novel α-glucuronidases, production hereof and their uses. |
| AUPO930697A0 (en) * | 1997-09-19 | 1997-10-09 | Walter And Eliza Hall Institute Of Medical Research, The | Catalytic antibodies and a method of producing same |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| DK1078051T3 (da) * | 1998-05-13 | 2008-04-07 | Domantis Ltd | Fagvisningsselektionssystem til selektion af korrekt foldede proteiner |
| WO2001055321A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| EP1328632A2 (en) | 2000-08-04 | 2003-07-23 | Eli Lilly And Company | C1q-related factor, homologous polypeptides and therapeutic uses thereof |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| JP4334866B2 (ja) | 2000-10-09 | 2009-09-30 | アイシス イノヴェイション リミテッド | 治療用抗体 |
| WO2002038796A2 (en) | 2000-11-08 | 2002-05-16 | Beth Israel Deaconess Medical Center, Inc. | Methods for determining protease cleavage site motifs |
| US20050208602A1 (en) * | 2001-08-10 | 2005-09-22 | Rosen Craig A | 89 human secreted proteins |
| US7439319B2 (en) | 2001-09-14 | 2008-10-21 | Burnham Institute For Medical Research | Selective substrates for matrix metalloproteinases |
| WO2003038083A1 (en) | 2001-10-29 | 2003-05-08 | Bayer Healthcare Ag | Regulation of human type i adenylate cyclase |
| WO2003068934A2 (en) | 2002-02-14 | 2003-08-21 | Rutter William J | Chimeric molecules for cleavage in a treated host |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US9079936B2 (en) * | 2003-07-01 | 2015-07-14 | University Of Maryland, Baltimore | Derivatives of APF and methods of use |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| CA2604885A1 (en) | 2005-04-07 | 2006-10-19 | Guoying Yu | Cacna1e in cancer diagnosis, detection and treatment |
| EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| CA2645347A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| AU2007308792B2 (en) * | 2006-10-27 | 2013-01-24 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| DE102008034659A1 (de) * | 2008-07-25 | 2010-02-04 | Schmidt-Seeger Gmbh | Rundbehälter zum Keimen oder Darren von Getreide |
| GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| US20100189727A1 (en) * | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| US8895702B2 (en) * | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| WO2010081173A2 (en) * | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| US9102925B2 (en) * | 2009-02-02 | 2015-08-11 | Washington State University | Compositions and methods for treating or preventing conditions and diseases associated with Mannheimia haemolytica |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
| US20120157824A1 (en) * | 2009-09-02 | 2012-06-21 | Nanoscale Corporation | Mri and optical assays for proteases |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US20110214205A1 (en) * | 2010-02-26 | 2011-09-01 | Monsanto Technology Llc. | Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits |
| MX369263B (es) * | 2010-05-20 | 2019-11-04 | Allergan Inc | Toxinas de clostridium degradables. |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| EP2709666B1 (en) | 2011-05-16 | 2021-07-14 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| CN110078827A (zh) | 2012-04-27 | 2019-08-02 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| SG11201408554QA (en) | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| US9487590B2 (en) * | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| WO2014107559A1 (en) | 2013-01-03 | 2014-07-10 | Branders.Com, Inc. | Methods and apparatus for determining a score value for criteria associated with a gift |
| CA2896282C (en) * | 2013-01-04 | 2021-07-20 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
| HK1222122A1 (zh) | 2013-04-22 | 2017-06-23 | Avelas Biosciences, Inc. | 选择性药物递送组合物及使用方法 |
| MX2015016329A (es) | 2013-05-28 | 2016-07-20 | Dcb Usa Llc | Bloqueador de anticuerpo para la inactivacion de farmaco de proteina. |
| KR102488220B1 (ko) | 2013-09-25 | 2023-01-12 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| KR102466591B1 (ko) | 2014-01-31 | 2022-11-14 | 싸이톰스 테라퓨틱스, 인크. | 마트립타제 및 ｕ-플라스미노겐 활성화인자 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| IL310251A (en) | 2015-05-04 | 2024-03-01 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof |
| SG10202110908WA (en) | 2015-05-04 | 2021-11-29 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
| US10233244B2 (en) | 2015-05-04 | 2019-03-19 | Cytomx Therapeutics, Inc. | Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| BR112019008223A2 (pt) | 2016-11-03 | 2019-07-16 | Bristol-Myers Squibb Company | anticorpos anti-ctla-4 ativáveis e usos dos mesmos |
| AU2018231127A1 (en) | 2017-03-09 | 2019-09-19 | Cytomx Therapeutics, Inc. | CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| SG11202105476XA (en) | 2018-12-06 | 2021-06-29 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
-
2014
- 2014-09-25 KR KR1020167010749A patent/KR102488220B1/ko active Active
- 2014-09-25 EP EP14783968.2A patent/EP3049111A2/en active Pending
- 2014-09-25 RU RU2016115542A patent/RU2715232C2/ru active
- 2014-09-25 NZ NZ718283A patent/NZ718283A/en unknown
- 2014-09-25 IL IL322893A patent/IL322893A/en unknown
- 2014-09-25 JP JP2016516911A patent/JP6915987B2/ja active Active
- 2014-09-25 AU AU2014324884A patent/AU2014324884B2/en active Active
- 2014-09-25 CA CA2925106A patent/CA2925106C/en active Active
- 2014-09-25 CN CN202410265535.5A patent/CN118165076A/zh active Pending
- 2014-09-25 KR KR1020257010278A patent/KR20250051130A/ko active Pending
- 2014-09-25 CA CA3214529A patent/CA3214529A1/en active Pending
- 2014-09-25 MX MX2016003957A patent/MX379106B/es unknown
- 2014-09-25 WO PCT/US2014/057523 patent/WO2015048329A2/en not_active Ceased
- 2014-09-25 KR KR1020237000930A patent/KR102790260B1/ko active Active
- 2014-09-25 IL IL291329A patent/IL291329B2/en unknown
- 2014-09-25 NZ NZ756892A patent/NZ756892A/en unknown
- 2014-09-25 CN CN202410265536.XA patent/CN118146306A/zh active Pending
- 2014-09-25 US US14/497,089 patent/US20150087810A1/en not_active Abandoned
- 2014-09-25 CN CN201480064185.0A patent/CN106163556B/zh active Active
-
2016
- 2016-03-24 IL IL244744A patent/IL244744B/en unknown
- 2016-03-28 MX MX2021000416A patent/MX2021000416A/es unknown
-
2018
- 2018-11-02 US US16/179,670 patent/US11814410B2/en active Active
-
2019
- 2019-09-24 JP JP2019173550A patent/JP2020015749A/ja active Pending
-
2020
- 2020-06-12 AU AU2020203910A patent/AU2020203910B2/en active Active
-
2021
- 2021-05-10 JP JP2021080015A patent/JP2021138707A/ja not_active Withdrawn
-
2023
- 2023-07-27 JP JP2023122426A patent/JP2023159099A/ja active Pending
- 2023-09-25 US US18/474,103 patent/US20240150478A1/en active Pending
- 2023-09-25 US US18/474,134 patent/US20240084022A1/en active Pending
- 2023-10-25 AU AU2023254931A patent/AU2023254931B2/en active Active
-
2024
- 2024-10-23 JP JP2024186751A patent/JP7806174B2/ja active Active
-
2026
- 2026-04-09 AU AU2026202666A patent/AU2026202666A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016115542A (ru) | Крепёжное устройство для эндоскопического контрольного устройства и способ его применения | |
| IL261432B1 (en) | Induced binding proteins and methods of use | |
| RU2015100656A (ru) | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения | |
| FI4176894T3 (fi) | Kimeerisiä tekijä viii -proteiineja ja niiden käyttötarkoituksia | |
| JP2016521707A5 (enExample) | ||
| JP2022064924A5 (enExample) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| NZ616761A (en) | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same | |
| JP2016505138A5 (enExample) | ||
| ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
| JP2018537415A5 (enExample) | ||
| RU2016106115A (ru) | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения | |
| AR108452A1 (es) | Moléculas de unión a antígeno que comprenden un trímero ligando de la familia de fnt y una fracción de unión a tenascina | |
| NO20063026L (no) | Antistoffer | |
| NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| RU2015156888A (ru) | Композиции и методы конъюгирования активируемых антител | |
| JP2016000731A5 (enExample) | ||
| EA200870555A1 (ru) | Слитые белки, их применение и способы их получения | |
| RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
| AR094149A1 (es) | Proteinas multifuncion que comprenden chm de clase i multivalente unido mediante disulfuro | |
| PE20140218A1 (es) | Composicion farmaceutica | |
| PE20190514A1 (es) | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 |